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Abstract
Background: Advances in the treatment of heart failure (HF) have resulted in reduced mortality and hospitalization 
rates. On the other hand, when hospitalized, patients are at high risk of death.
Objective: As there are few studies in this group of patients in Brazil, we analyzed the numbers of hospitalization and 
deaths due to HF in the Brazilian Public Health System (SUS) in the city of São Paulo. 
Methods: Historical prospective study carried out between 1992 and 2010. The data were obtained from DATASUS. 
We used Chi-square and t tests for comparison between the periods 1992-1993 and 2008-2009 and logistic regression 
models when appropriate. The level of significance was set at 5%. 
Results: There was a 32% decrease in the number of hospitalizations for HF between 1992-1993 and 2008-2009 (p = 
0.002). The in-hospital mortality rate for HF was 15%, with a 15% increase in the period (p = 0.004). Between 1992 
and 1993, the mean time of hospitalization for HF was 8.8 days. Between 2008 and 2009, it was 11.3 days (p = 0.001). 
August was the month with the highest incidence of hospitalizations for HF, 20% higher than in February, the month 
with the lowest incidence (p = 0.041).
Conclusion: This study showed changes in trends of hospitalization for HF and mortality over the last two decades. We 
emphasize important implications: 1: 32% decrease in the number of hospitalizations for HF in SUS hospitals in São 
Paulo; 2: 25% increase in hospitalization time, and 3: seasonal pattern of hospitalization for HF, with a peak in the third 
quarter.  (Arq Bras Cardiol 2011;97(5):402-407)
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Patients who require hospitalization, however, are at high 
risk for death and re-hospitalization9, 10. There are few studies 
directed specifically at this group of patients, and information 
about the clinical features and prognosis in this population 
is still limited. Thus, this study aims at analyzing the number 
of hospitalizations and deaths due to HF between 1992 and 
2010 in SUS hospitals in the city of São Paulo. 
Methods
Historical prospective study carried out from 1992 to 2010. 
Epidemiological data were obtained from the database of the 
Informatics Department of SUS (DATASUS), based on the 
“Authorization for Hospitalization” (AIH) form, a document filled 
out by the physician in charge at the time of hospitalization. We 
included data on patients older than 20 years whose primary 
diagnosis for hospital admission was HF. Population estimates 
were obtained from the demographic censuses of the Brazilian 
Institute of Geography and Statistics (IBGE). 
The in-hospital mortality rate for HF was considered the 
ratio between the number of deaths due to HF and the number 
of patients admitted with a primary diagnosis of HF in the 
corresponding period. Calculation of the population mortality 
rate for HF was obtained by dividing the number of in-hospital 
Introduction
In recent decades, heart failure (HF) has emerged as a 
public health problem1. Kannel2, based on epidemiological 
data obtained from the Framingham Heart Study, estimates 
there are five million patients with HF in the United States, 
with an incidence of approximately 400,000 new cases per 
year. In Brazil, the same magnitude is presumed for this 
disease. Data from the Ministry of Health in 2006 suggest a 
prevalence of two million patients with HF, which is a major 
cause of hospitalization among the cardiovascular diseases 
in the Brazilian Public Health System (SUS)3. 
On the other hand, several clinical trials have shown that 
the use of beta-blockers (ßb), angiotensin-converting enzyme 
inhibitors (ACEi), aldosterone inhibitors, associated with the 
use of implantable cardioverters and cardiac resynchronizers 
can increase survival and reduce hospitalization rates4-8. 
402
Original Article
Arq Bras Cardiol 2011;97(5):402-407
Godoy et al
Heart Failure Indicators
deaths due to HF by the city population in the corresponding 
period. The Chi-square or t tests were used for comparison 
between the periods 1992-1993 and 2008-2009 and logistic 
regression models were used when appropriate. The level of 
significance was set at 5%. 
Results
Between 1992 and 2010, in SUS hospitals in São 
Paulo, a total of 194,098 patients were hospitalized for 
HF (10,783 patients/year, ± 2,740) of whom 95,219 were 
females (49.0%), with a predominance of patients aged 60 
and 79 years (Table 1). In the historical series, considering 
the periods 1992-1993 and 2008-2009, there was a 32% 
decrease in the number of hospitalizations for HF (p = 
0.002) (Figure 1). 
The in-hospital mortality rate for HF during the 
period was 15% (± 1.02%), an increase of 15% over the 
observation period (p = 0.004) (Figure 2). The population 
mortality rate for HF had a 71% decrease in the period: 
from 1.91 deaths for HF/10.000 inhabitants between 1992 
and 1993 to 1.36/10,000 inhabitants in 2008 to 2009 
(p = 0.03) (Figure 3).  
The mean hospital stay for HF was 10 days (± 1.0), with 
a progressive increase during the observation period (Figure 
4). In the 2008-2009 period, the mean hospital stay was 
11.3 days, 25% higher than in the 1992-1993 period (8.8 
days) (p = 0.001). 
Table 1 – Description of the population hospitalized for HF in public 
hospitals in São Paulo between 1992 and 2010
n %
Female sex 95.219 49.0
Hospitalizations due to HF
20 to 29 years 4,142 2.0
30 to 39 years 8,963 5.0
40 to 49 years 17,726 9.0
50 to 59 years 30,796 16.0
60 to 69 years 41,324 21.0
70 to 79 years 41,671 21.0
80 years and older 30,223 16.0
Deaths due to HF
20 to 29 years 449 2.0
30 to 39 years 912 4.0
40 to 49 years 1,739 8.0
50 to 59 years 3,350 16.0
60 to 69 years 5,617 27.0
70 to 79 years 7,311 35.0
80 years and older 7,069 34.0 
HF - Heart failure. 
Figure 1 – Total number of hospitalizations for heart failure in the city of São Paulo between 1992 and 2010; * P = 0.002.
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Figure 2 – Hospital mortality rate for HF in the city of São Paulo between 1992 and 2010; * P = 0.004.
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Figure 3 – Coefficient of population mortality for heart failure in the city of São Paulo between 1992 and 2010 (per 10,000 inhabitants); * P = 0.03.
Co
ef
fic
ie
nt
 o
f m
or
ta
lit
y 
du
e 
to
 H
F
Year
As shown in Figure 5, there was a seasonal variation in the 
number of hospitalizations for HF in São Paulo, with the highest 
rates seen in July, August and September. The month with the 
highest incidence of hospital admissions was August, with 
18,466 admissions, 20% higher than in February, the month 
with the lowest incidence (p = 0.041). 
Discussion
This analysis showed significant decrease in hospital admissions 
and population mortality rates for HF in São Paulo. As our study 
covered the period of consolidation of modern therapy for HF, in 
which the decrease in mortality and need for hospitalization has 
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been repeatedly demonstrated4-8, it is reasonable to suppose that 
these results have been obtained due to the more appropriate 
use of guidelines for HF treatment11 offered by physicians in the 
public healthcare system of the municipality. 
The MAHLER study12 showed that the simple fact that 
prescribing physicians adhered to the recommendations of 
European guidelines was a prognostic predictor in patients 
with HF. Although several international studies have shown 
that the prescription of treatments recommended for HF is 
still suboptimal13,14, in the EVEREST study15, at the moment 
of randomization, 93% of the South Americans patients 
used ACEi and 56%, ßb. In a Brazilian study, Baliero et al16 
Figure 4 – Days of hospitalization for heart failure in the city of São Paulo between 1992 and 2010; * P = 0.001.
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Figure 5 – Total number of hospitalizations for heart failure in the city of São Paulo between 1992 and 2010, distributed by month of hospital admission.
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observed the use of ACEi and ßb in more than 70% of the 
patients diagnosed with HF.  
Throughout the analyzed period, we observed an 
increased hospital mortality rate and hospitalization time for 
HF. Inversely, Bueno et al17 observed that in North-American 
patients, there was a decreased length of hospital stay and 
hospital mortality for HF over 14 years. However, these 
authors found significantly increased in-home mortality and 
re-hospitalization rates. These findings suggest a growing 
complexity in patients hospitalized for HF, particularly those at 
higher risk, such as elderly patients, those with kidney failure 
and chronic lung disease18.  
On the other hand, observations of the ADHERE19 registry 
provide clues on how to improve the quality of the offered 
medical care. In this study, the decrease in mortality rates and 
length of hospitalization was obtained concomitantly with the 
increase in compliance with the recommendations of healthcare 
quality in HF, such as evaluation of ventricular function during 
hospitalization and early prescription of ACEi20.
We also observed a significant increase in hospitalizations 
for HF during the winter months, a pattern previously 
reported in studies of countries with temperate climates21-23. 
Several mechanisms are involved in this pattern: increased 
neurohumoral activation at lower temperatures, decreased 
water loss by transpiration and perspiration and, especially, 
increased incidence of respiratory infections24. These data 
reinforce the need for strict control of hydrosaline intake in 
winter and of vaccination against Influenza and Pneumococcus, 
particularly in cities that exhibit great climatic changes among 
the seasons, as shown in the III Brazilian Guidelines on Chronic 
Heart Failure4.  
Our study has limitations: the reliability of the 
information provided by the DATASUS database is restricted 
by the level of accuracy and completeness of AIH forms 
filled out by physicians. In addition, the observations 
obtained in this study cannot be generalized to the entire 
city of São Paulo, as only SUS hospitals in the city were 
included in the analysis. Despite these limitations, our 
study showed the possibility to assess changes in trends 
of hospitalization and mortality rates for HF over the past 
two decades.  
These observations allow us to monitor the effectiveness 
of the offered medical care aiming at tailoring policies 
regarding the treatment of patients with HF.
In this context, we highlight three important implications: 
1st: reduction of 32% in the number of hospitalizations 
for HF in SUS hospitals in São Paulo, 2nd: 25% increase in 
hospitalization time and 3rd: seasonal pattern of hospitalization 
for HF, showing a peak in the third quarter. 
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